Altamonte Springs, Fla.-based AdventHealth will use artificial intelligence to build a patient registry biobank to deliver targeted treatment for COVID-19 patients.
Five details:
1. AdventHealth partnered with Berg, a clinical-state biotech company, to develop the patient registry.
2. The biobank registry will include comprehensive EHR records for patients who test positive for AdventHealth COVID-19, including hospital length of stay, medications and outcomes.
3. Using the Berg AI platform, AdventHealth will monitor clinical data to understand which health factors increase the risk for COVID-19 illness.
4. Eventually, the partners aim to include enterprisewide data to conduct an exploratory analysis of chronically administered medications associated with better outcomes and lower SARS-CoV-2 infection rates.
5. The partners will use the framework created in their precision medicine partnership to improve outcomes for non-alcoholic fatty liver disease and sarcopenia.
More articles on health IT:
Northwell AI tool allows nurses to strategically monitor overnight vitals
Mount Sinai builds machine learning models to predict COVID-19 mortality
Google launches AI tools for healthcare to streamline document review, analysis